Psychological effects of Prolactinomas

Click here to visit a website with two relevant articles:

There is a 78 page soft cover book Emotional Aspects of Pituitary Disease published in 1998 by S. KARGER AG, BASEL, Switzerland - Medical and Scientific Publishers. ISBN 3-8055-6664-6 Price in the USA is USD $41.75 (United States Dollars), in Germany DEM 57 (Germany Deutsche Marks), and elsewhere in the world it is CHF 48 (Switzerland Francs) which as at 6th. July 2000 converts to CDN $43.88 (Canada Dollars). You can visit the publishers web site for a full description by clicking on the underlined book name above (you can also order from there by emailing the above ISBN and your complete postal address to orders@karger.ch). Currency exchange rates change frequently, to convert based on today's rates visit The Universal Currency Converter. This book is also available from the Pituitary Tumor Network Association (they have a more detailed description of this book posted on their website than on the publisher's website) at a cost of USD $39.75 (CDN $59.04) for non members or USD $29.75 (CDN $44.18) for members, but annual membership costs USD $45.00 (CDN $66.83) for US residents and USD $55.00 (CDN $81.69) for non USA residents. Residents of countries other than the USA might find it cheaper to order direct from the publisher (for example, CHF 48 converts to CDN $43.88 and no membership fees required). All currency conversion examples are based on exchange rates as at 6th. July 2000.

The following is not related to the book, it is an abstract I found a few years ago:


UI  - 97340097
AU  - Peace KA; Orme SM; Sebastian JP; Thompson AR; Barnes S; Ellis A; Belchetz
      PE
TI  - The effect of treatment variables on mood and social adjustment in adult
      patients with pituitary disease.
SO  - Clin Endocrinol (Oxf) 1997;46(4):445-50
AD  - Department of Endocrinology, General Infirmary at Leeds, UK.
AB  - OBJECTIVE: Studies of mood in hypopituitary adults have yielded
      inconsistent results. This investigation was carried out to
      investigate whether treatment characteristics may be responsible for
      the inconsistent results. DESIGN AND MEASUREMENTS: We compared three
      groups of patients with a group of matched healthy controls on
      self-report measures of mood and social adjustment (Beck depression
      inventory, State-trait anxiety inventory, Social adjustment scale
      (modified)) and a measure of quality of life (Nottingham health
      profile, NHP). PATIENTS: The patient groups were those treated with
      transfrontal surgery (n = 23), transsphenoidal surgery (n = 23) or
      medication only (n = 23). In addition, a close informant of each
      subject was asked to complete a social adjustment measure about the
      subject's level of adjustment. RESULTS: On the self-report mood and
      social adjustment measures and the emotion sub-scale of the NHP, the
      transsphenoidal and medication patient groups rated themselves as
      being more depressed, anxious and having poorer social adjustment
      than the transfrontal or control groups. The close informants,
      however, rated all three patient groups as having poorer social
      adjustment than the controls. Patients treated with surgery and
      without radiotherapy reported fewer symptoms of depression than those
      treated with radiotherapy. Realistic self-appraisal of social
      adjustment in surgical patients was found only in those treated with
      transsphenoidal surgery without radiotherapy. CONCLUSIONS: Patients
      treated for pituitary tumour, excepting those treated with transfron-
      tal surgery and to a lesser extent those treated with radiotherapy,
      suffer from mild mood disturbance and self-perceived decreased social
      adjustment. All patient groups are seen by others as having decreased
      social adjustment, raising the possibility that the transfrontal
      patients and possibly those who have had radiotherapy, lack insight.
      This may explain some of the discrepancies in the previous literature
      and needs to be taken into account when using self-report measures
      with these patients.


Return to my Treatment of Prolactinomas page

This Page Last Updated on 11th. July, 2000